FDA Approves Olaparib for HRR Gene-Mutated mCRPC

The FDA approved olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.

Source: CancerNetwork - May 20, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news